申请人:MERCK SHARP & DOHME CORP.
公开号:US20210069288A1
公开(公告)日:2021-03-11
Disclosed are compounds of Formula A, or a pharmaceutically acceptable salt thereof:
where A, X, R
1
, and R
2
are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.